Features of the Composition of Cytokines of Various Biological Effects in Patients with Uveal Melanoma: Analysis of Blood Serum. Part 2
https://doi.org/10.18008/1816-5095-2022-2-378-383
Abstract
Purpose. Conduct extended analysis of cytokine status and its role in inflammatory processes in uveal melanoma based on multiplex analysis of blood serum.
Patients and methods. Immunological studies of blood serum and lacrimal fluid were performed in 80 patients with uveal melanoma and 38 healthy donors (control group). The average age of the surveyed was 53.7 ± 12.2 years. Group 1 included 32 patients with small-sized choroidal melanoma (T1NoMo), group 2 consisted of 26 patients with medium-sized tumors (T2NoMo), group 3 — 22 patients with large tumor size (T3NoMo). Cytokine content was determined in blood serum by the method of multiplex analysis on the xMAP platform in the Luminex xPONENT 3.1 program using 47 plex kits (ProcartaPlex, eBioscience, Austria).
Results. In blood serum — increase of pro-inflammatory (LIF, RANTES, IP-10), anti-inflammatory (TGF-1β), proliferative (IL-15), pro-tumor (EGF), angiogenic (PIGF-1 and SDF-1α) cytokines compared with control group, p < 0.05.
Conclusion. In response to the manifestation and growth of uveal melanoma, many chemoattractant mediators of proinflammatory, angiogenic, proliferative action are produced that promote metastasis. The study of cytokines at the systemic level in serum leads to a deeper understanding of the pathophysiology of carcinogenesis and to facilitate the development of targeted therapies for inhibiting tumor growth.
About the Authors
V. V. Neroev
Helmholtz National Medical Research Eye Diseases Center
Russian Federation
Russian Federation
acad. оf Russian Academy of Sciences, Professor, director,
Sadovaya-Chernogryazskaya str., 14/19, Moscow, 105062
S. V. Saakyan
Helmholtz National Medical Research Eye Diseases Center
Russian Federation
Russian Federation
MD, Professor, head of the Ophthalmo-oncology and radiology department,
Sadovaya-Chernogryazskaya str., 14/19, Moscow, 105062
L. A. Katargina
Helmholtz National Medical Research Eye Diseases Center
Russian Federation
Russian Federation
MD, Professor, head of the Eye pathology in children department, deputy director,
Sadovaya-Chernogryazskaya str., 14/19, Moscow, 105062
N. V. Balatskaya
Helmholtz National Medical Research Eye Diseases Center
Russian Federation
Russian Federation
PhD in Biology, leading researcher, head of the Immunology and virology department,
Sadovaya-Chernogryazskaya str., 14/19, Moscow, 105062
I. G. Kulikova
Helmholtz National Medical Research Eye Diseases Center
Russian Federation
Russian Federation
senior researcher of the immunology and virology department,
Sadovaya-Chernogryazskaya str., 14/19, Moscow, 105062
E. B. Myakoshina
Helmholtz National Medical Research Eye Diseases Center
Russian Federation
Russian Federation
PhD, senior research officer of the ophthalmology and radiology department,
Sadovaya-Chernogryazskaya str., 14/19, Moscow, 105062
References
1. Hanahan D., Weinberg R.A. The Hallmarks of Cancer. Cell. 2000;100:57-70. DOI: 10.1016/s0092-8674(00)81683-9
2. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073–1081. DOI: 10.1093/carcin/bgp127
3. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature. 2008 Jul 24;454(7203):436–444. DOI: 10.1038/nature07205
4. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol. 2012;30:677–706. DOI: 10.1146/annurev-immunol-020711-075008
5. Savelieva O.E., Perelmuter V.M., Tashireva L.A., Denisov E.V., Isaeva A.V. Inflammation as a therapeutic target in the complex treatment of malignant tumors. Siberian Journal of Oncology = Sibirskij onkologicheskij zhurnal. 2017;16(3):65–78 (In Russ.). DOI: 10.21294/1814-4861-2017-16-3-65-78
6. Clinical guidelines “Uveal melanoma”, 2020 (In Russ.). https://oncology-association.ru/files/newclinical-guidelines/uvealnaja_melanoma.pdf
7. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., Zhu Z., Hicklin D., Wu Y., Port J.L., Altorki N., Port E.R., Ruggero D., Shmelkov S.V., Jensen K.K., Rafii S., Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature. 2005 Dec 8;438(7069):820–827. DOI: 10.1038/nature04186.8
8. Saakyan S.V., Zakharova G.P., Myakoshina E.B. Cellular microenvironment of uveal melanoma: clinical and morphological correlations and predictors of poor prognosis. Molecular Medicine = Molekulyarnaya meditsina. 2020;18(3):27–33 (In Russ.). DOI: 10.29296/24999490-2020-03-04
9. Saakyan S.V., Zakharova G.P., Myakoshina E.B. Mast cells in the microenvironment of uveal melanoma. Archive of pathology = Arkhiv patologii. 2019;81(6):63–70 (In Russ.). DOI:org/10.17116/patol20198106163
10. Myakoshina E.B., Kulikova I.G., Balatskaya N.V., Katargina L.A., Saakyan S.V. Transforming growth factor TGF-β in different clinical course of initial choroidal melanoma before and after organpreserving treatment. Ophthalmic surgery = Oftal’mokhirurgiya. 2020;3:58–64 (In Russ.). DOI: 10.25276/0235-4160-2020-3-58-64
11. Bierie В., Moses H.L. TGF-beta and cancer. Cytokine growth factor Rev. 2006;17:29–40.
12. Siegel Р., Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer. 2003;3:807–821. DOI: 10.1038/nrc1208
13. Kawakami K., Kawakami M., Joshi B.H., Puri R.K. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res. 2001;61:6194–6200.
14. Hendrix M.J.C., Seftor E.A., Seftor R.E.B., Kirschmann D.A., Gardner L.M., Boldt H.C., Meyer M., Pe’er J., Folberg R. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/ scatter factor (HGF/SF). Am J Pathol. 1998;152:855–863.
15. Monique H., Hurks H., Metzelaar-Blok J.A., Barthen E. R., Zwinderman A.H., WolffRouendaal D., Keunen J.E., Jager M.J. Expression of epidermal growth factor receptor: risk factor in uveal melanoma. Invest Ophthalmol Vis Sci. 2000;41:2023–2027.
16. Franco R., Botti G., Mascolo M., Loquercio G., Liguori G., Ilardi G., Losito S., Mura A.L., Calemma R., Ierano C., Bryce J., D’Alterio C., Scalaet S. CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression. Frontiers in bioscience (Elite edition). 2010;2:13–21. DOI: 10.2741/e60
Review
For citations:
Neroev V.V., Saakyan S.V., Katargina L.A., Balatskaya N.V., Kulikova I.G., Myakoshina E.B. Features of the Composition of Cytokines of Various Biological Effects in Patients with Uveal Melanoma: Analysis of Blood Serum. Part 2. Ophthalmology in Russia. 2022;19(2):378-383. (In Russ.) https://doi.org/10.18008/1816-5095-2022-2-378-383
Views:
342
Email this article 